Anti-tumor effects of fusion vaccine prepared by renal cell carcinoma 786-O cell line and peripheral blood dendritic cells of healthy volunteers in vitro and in human immune reconstituted SCID mice

Cellular Immunology

Volumn 262, Issue 2, 2010, Pages 112-119

  Hu, Zhi ^a   Liu, Shihui ^a   Mai, Xuancheng ^a   Hu, Zili ^a   Liu, Chuan ^a  

^a CHONGQING MEDICAL UNIVERSITY   (China)

Author keywords

Dendritic cells; Fusion vaccine; Immunotherapy; Renal cell carcinoma; SCID mice

Indexed keywords

CANCER VACCINE; CD86 ANTIGEN; DENDRITIC CELL VACCINE; HLA DR ANTIGEN; INTERLEUKIN 12; MACROGOL;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIGEN EXPRESSION; ANTIGEN PRESENTING CELL; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER IMMUNOTHERAPY; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL CYCLE G2 PHASE; CELL FUSION; CELL KILLING; CELL PROLIFERATION; CONTROLLED STUDY; CYTOKINE RELEASE; DENDRITIC CELL; DISEASE MODEL; FEMALE; HISTOPATHOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; KIDNEY CARCINOMA; LYMPHOCYTE PROLIFERATION; MALE; MIXED LYMPHOCYTE REACTION; MOUSE; NONHUMAN; PRIORITY JOURNAL; SCID MOUSE; T LYMPHOCYTE; TARGET CELL; TREATMENT OUTCOME; TUMOR CELL; TUMOR IMMUNITY; TUMOR VOLUME; UPREGULATION; VOLUNTEER;

ANIMALS; CANCER VACCINES; CARCINOMA, RENAL CELL; CELL CYCLE; CELL FUSION; CELL LINE, TUMOR; CELLS, CULTURED; DENDRITIC CELLS; FEMALE; HLA ANTIGENS; HUMANS; INTERLEUKIN-12; MALE; MICE; MICE, SCID; NEOPLASM TRANSPLANTATION; POLYETHYLENE GLYCOLS; RANDOM ALLOCATION;

MUS;

EID: 77950861300     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2010.01.004     Document Type: Article

References (20)

1. Richard D., Lehmann F., Jennings C., et al. Allogeneic stem cell transplantation for renal cell carcinoma. Curr. Opin. Urol. 2001, 11(5):495-502.
2. Pantuck A.J., Zisman A., Belldegrun A.S. The changing natural history of renal cell carcinoma. J. Urol. 2001, 166:1611-1623.
3. Narumi S., Tebo J.M., Finke J.H., et al. IFN-gamma and IL-2 cooperatively activated NF Kappa B in murine peritoneal macrophages. J. Immunol. 1992, 1499:529-534.
4. Lummen G., Goepel M., Mollhoff S., et al. Phase II study of interferon-gamma versus interleukin-2 and interferon-alpha 2b in metastatic renal cell carcinoma. J. Urol. 1996, 155(2):455-458.
5. Groux H., Fournier N., Cottrez F. Role of dendritic cells in the generation of regulatory T cells. Semin. Immunol. 2004, 16(2):99-106.
6. Orentas R.J., Schauter D., Bin Q., et al. Electronfusion of a weakly immunogenic neuroblastoma with dendritic cells produces a tumor vaccine. Cell. Immunol. 2001, 213(1):4-13.
7. Kim G.Y., Chae H.J., Kim K.H., et al. Dendritic cell-tumor fusion vaccine prevents tumor growth in vivo. Biosci. Biotechnol. Biochem. 2007, 71(1):215-221.
8. Koido S., Ohana M., Liu C., et al. Dendritic cells fused with human cancer cells: morphology, antigen expression, and T cell stimulation. Clin. Immunol. 2004, 113(3):261-269.
9. Koido S., Hara E., Homma S., et al. Dendritic cells fused with allogeneic colorectal cancer cell line present multiple colorectal cancer-specific antigens and induce antitumor immunity against autologous tumor cells. Clin. Cancer Res. 2005, 11(21):7891-7900.
10. Avigan D. Dendritic cell-tumor fusion vaccines for renal cell carcinoma. Clin. Cancer Res. 2004, 10(18 Pt 2):6347S-6352S.
11. Parkhurst M.R., Depan C., Riley J.P., et al. Hybrids of dendritic cells and tumor cells generated by electrofusion simultaneously present immunodominant epitopes from multiple human tumor-associated antigens in the context of MHC class I and class II molecules. Immunology 2003, 170(10):5317-5325.
12. Marten A., Renoth S., Heinicke T., et al. Allogeneic dendritic cells fused with tumor cells: preclinical results and outcome of a clinical phase trial in patients with metastatic renal cell carcinoma. Hum. Gene Ther. 2003, 14(5):483-494.
13. Barbuto J.A., Ensina L.F., Neves A.R., et al. Dendritic cell-tumor cell hybrid vaccination for metastatic cancer. Cancer Immunol. Immunother. 2004, 53(12):1111-1118.
14. Troy A.J., Davidson P.J., Atkinson C.H., et al. CD1a dendritic cells predominate in transition cell carcinoma of bladder and kidney but are minimally activated. J. Urol. 1999, 161(6):1962-1967.
15. Takeda A., Homma S., Okamoto T., et al. Immature dendritic cell/tumor cell fusions induce potent antitumour immunity. Eur. J. Clin. Invest. 2003, 33(10):897-904.
16. Williamson L.M., Warwick R.M. Transfusion-associated graft-versus-host disease and its prevention. Blood Rev. 1995, 9:251-261.
17. Gitlitz B.J., Belldegrun A.S., Zisman A., et al. Apilot trial of tumor lysate-loaded dendritic cells for the treatment of metastatic renal cell carcinoma. Immunology 2003, 26:412-419.
18. Pandha H.S., John R.J., Hutchinson J., et al. Dendritic cell immunotherapy for urological cancers using cryopreserved allogeneic tumor lysate-pulsed cell. BJU Int. 2004, 94(3):412-418.
19. Gilboa E., Vieweg J. Cancer immunotherapy with mRNA-transfected dendritic cells. Immunol. Rev. 2004, 1999(11):251-263.
20. Panther E., Corinti S., Idzko M., et al. Adenosine affects expression of membrane molecules, cytokine and chemokine release, and the T-cell stimulatory capacity of human dendritic cells. Blood 2003, 101:3985-3990.